ONCOLYTICS BIOTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.46 CAD | -5.19% |
|
-7.59% | -18.44% |
| Apr. 11 | Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA | CI |
| Apr. 11 | Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA | MT |
Chart calendar Oncolytics Biotech Inc.
485d.w7svao3_mHg0HKJWXBZxRcinDxPvtt4PTFIu7xJF774.goIXWL3GtRl8LdVjA2UkaPnKdWSg7LNaARxDlSE12fuc81cwyZzzK0FS5w~dca4d54808db9210ce372857323b9f7b
Upcoming events on Oncolytics Biotech Inc.
Past events on Oncolytics Biotech Inc.
| Today 09:00 am | CG Horizons in Oncology Virtual Conference - Viral Approaches in Oncology |
| 2024-03-07 04:30 pm | Q4 2023 Earnings Call |
| 2024-03-07 04:01 pm | Q4 2023 Earnings Release |
| 2024-03-01 11:30 am | Cancer Advocacy Group of Louisiana NeauxCancer Conference |
| 2023-11-08 | International Multidisciplinary Anal Cancer Conference |
| 2023-11-04 12:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number - 582 |
| 2023-11-03 08:30 am | Q3 2023 Earnings Call |
| 2023-11-03 07:00 am | Q3 2023 Earnings Release |
| 2023-10-22 | European Society for Medical Oncology Congress - Abstract Number:1623P |
| 2023-10-21 | European Society for Medical Oncology Congress - Abstract Number:619P |
| 2023-09-27 08:35 am | Cantor Global Healthcare Conference - Fireside Chat |
| 2023-09-12 09:30 am | H.C. Wainwright Global Investment Conference |
| 2023-08-14 08:30 am | Q2 2023 Earnings Call |
| 2023-08-14 07:00 am | Q2 2023 Earnings Release |
| 2023-08-10 12:00 pm | Canaccord Genuity Growth Conference |
| 2023-06-22 12:00 pm | Maxim Group Virtual Healthcare Conference |
| 2023-06-05 08:00 am | Investor Meeting - Key Opinion Leader |
| 2023-06-03 02:15 pm | American Society of Clinical Oncology Conference - Abstract Number: 1012 |
| 2023-05-09 04:00 pm | Annual General Meeting |
| 2023-05-05 08:30 am | Q1 2023 Earnings Call |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million CAD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,86 |
|
EBITDA Million CAD | Released Forecast Spread | -20,6 -25,5 19.33% | -25,0 -21,8 -14.72% | -26,1 -26,3 0.56% | -26,5 -24,3 -9.19% | -33,4 -35,3 5.42% | -42,0 |
|
EBIT Million CAD | Released Forecast Spread | -20,7 -17,4 -18.59% | -26,1 -23,6 -10.67% | -26,2 -28,3 7.23% | -26,9 -24,7 -8.81% | -33,8 -35,3 4.37% | -39,2 |
|
Earnings before Tax (EBT) Million CAD | Released Forecast Spread | -33,1 -17,4 -90.62% | -22,5 -20,2 -11.42% | -26,3 -26,6 1.26% | -24,8 -22,5 -9.98% | -27,7 -33,9 18.38% | -36,2 |
|
Net income Million CAD | Released Forecast Spread | -33,1 -19,5 -70.12% | -22,5 -20,1 -12.19% | -26,3 -25,7 -2.37% | -24,8 -23,7 -4.97% | -27,8 -33,9 18.22% | -36,2 |
|
EPS CAD | Released Forecast Spread | -1,50 -0,87 -72.91% | -0,56 -0,49 -14.75% | -0,49 -0,46 -5.95% | -0,43 -0,40 -7.45% | -0,41 -0,50 18.39% | -0,44 |
| Announcement Date | 05/03/20 | 05/03/21 | 03/03/22 | 03/03/23 | 07/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million CAD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 1,50 | |
|
EBITDA Million CAD | Released Forecast Spread | -7,43 -9,49 21.68% | -6,21 -8,30 25.17% | -5,95 -6,62 10.12% | -5,96 -7,00 14.83% | -8,41 -6,10 -37.85% | -6,64 -8,44 21.35% | -7,06 -7,18 1.68% | -10,9 -7,35 -48.88% | -8,74 -10,7 18.3% | -8,90 | -9,90 | -11,0 | -14,1 | |
|
EBIT Million CAD | Released Forecast Spread | -7,45 -9,54 21.85% | -6,31 -8,30 23.99% | -6,05 -6,62 8.64% | -6,06 -6,57 7.72% | -8,51 -6,35 -34.09% | -6,73 -8,16 17.44% | -7,16 -7,17 0.13% | -11,0 -7,44 -48.41% | -8,85 -10,4 15.08% | -8,81 | -9,31 | -9,93 | -11,2 | |
|
Earnings before Tax (EBT) Million CAD | Released Forecast Spread | -7,71 -8,40 8.25% | -6,78 -8,19 17.23% | -5,07 -6,88 26.32% | -4,40 -6,48 32.05% | -8,50 -6,27 -35.49% | -6,44 -8,14 20.89% | -7,39 -6,99 -5.74% | -9,92 -7,32 -35.41% | -3,91 -10,2 61.54% | -8,52 | -8,98 | -9,59 | -9,16 | |
|
Net income Million CAD | Released Forecast Spread | -7,75 -8,40 7.75% | -6,78 -8,19 17.23% | -5,09 -6,88 25.96% | -4,41 -6,48 32.01% | -8,55 -6,27 -36.4% | -6,44 -8,14 20.89% | -7,44 -6,99 -6.41% | -9,93 -7,32 -35.51% | -3,95 -10,2 61.12% | -8,52 | -8,98 | -9,59 | -9,16 | |
|
EPS CAD | Released Forecast Spread | -0,14 -0,13 -10.52% | -0,12 -0,14 16.28% | -0,09 -0,11 15.63% | -0,08 -0,11 27.27% | -0,15 -0,10 -54.64% | -0,10 -0,13 23.43% | -0,12 -0,11 -5.82% | -0,14 -0,11 -29.39% | -0,05 -0,15 65.61% | -0,11 | -0,11 | -0,12 | -0,10 | -0,12 |
| Announcement Date | 03/03/22 | 05/05/22 | 11/08/22 | 07/11/22 | 03/03/23 | 05/05/23 | 14/08/23 | 03/11/23 | 07/03/24 | - | - | - | - | - |
More events
Past sector events for Oncolytics Biotech Inc.
| 2024-04-10 04:10 pm | PHARVARIS N.V.: Q4 2023 Earnings Release |
| 2024-04-10 01:22 am | POLARIS GROUP: March 2024 Sales and Revenue Release |
| 2024-04-02 02:30 am | ABIVAX: Q4 2023 Earnings Release |
| 2024-04-01 09:00 am | BIOMEA FUSION, INC.: Q4 2023 Earnings Release |
| 2024-03-28 10:42 pm | ALPHAMAB ONCOLOGY: Q4 2023 Earnings Release |
| 2024-03-28 04:28 pm | CENTESSA PHARMACEUTICALS PLC: Q4 2023 Earnings Release |
| 2024-03-28 04:05 pm | ARRIVENT BIOPHARMA, INC.: Q4 2023 Earnings Release |
| 2024-03-28 07:10 am | HANGZHOU TIGERMED CONSULTING CO., LTD: Q4 2023 Earnings Release |
| 2024-03-27 | JOINN LABORATORIES(CHINA)CO.,LTD.: Q4 2023 Earnings Release |
| 2024-03-27 10:25 am | PHARMARON BEIJING CO., LTD.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ONC Stock
- Calendar Oncolytics Biotech Inc.
